Subject Areas on Research
- A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection.
- Accumulation of Cytotoxic CD16+ NK Cells in Simian Immunodeficiency Virus-Infected Lymph Nodes Associated with In Situ Differentiation and Functional Anergy.
- Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro.
- Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
- CD4+/CD56+ hematodermic neoplasm: presentation of 2 cases and review of the concept of an uncommon tumor originated in plasmacytoid dendritic cells expressing CD123 (IL-3 receptor alpha).
- CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells.
- Characterization of uterine NK cells in women with infertility or recurrent pregnancy loss and associated endometriosis.
- High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
- Human placental cytotrophoblasts attract monocytes and CD56(bright) natural killer cells via the actions of monocyte inflammatory protein 1alpha.
- Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs.
- Induction of CD56 and TCR-independent activation of T cells with aging.
- Metastatic Merkel cell carcinoma (MCC) of pancreas and breast: a unique case.
- Natural killer cells in vernal keratoconjunctivitis.
- Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.
- Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9.
- Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
- Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.